에서 실시간으로 운영 중이에요! 자세히 알아보기

Puma Biotechnology

PBYI

시가총액 US$5.07억

9.83 USD

-0.69

6.56%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-6.56%

5일

-4.75%

1개월

4.69%

3개월

17.02%

6개월

35.77%

연초 이후

70.36%

1년

81.7%

5년

66.05%

10년

-81.2%

소개: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

직원 수: 179

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 31.3%

중립 62.5%

부정적 6.3%

Zacks Investment Research

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Zacks Investment Research

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.